Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled...
Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price […]
HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024,...
Compugen Ltd. has entered another collaboration, this time exclusively licensing a preclinical antibody program against an IL-18 binding protein with Gilead Sciences Inc. Compugen will handle ongoing preclinical development and a phase I study of COM-503 to treat tumors, then Gilead receives to sole right to further continue developing the asset. Compugen is getting an up-front $60 million and is eligible for a $30 million milestone payment should the IND clear in 2024. Compugen also is eligible for $758 million in development, regulatory and commercial milestones, putting the deal value at $8...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...